News

Observe Medical ASA: Notification of transaction by close associate to primary insider and disclosure of large shareholding

Oslo, 5 December 2024: Reference is made to the stock announcement published by Observe Medical ASA (the "Observe Medical") on 5 December 2024 regarding the final result of the subsequent offering and the partial conversion to shares of certain loans from Navamedic ASA ("Navamedic") to Observe Medical. Navamedic currently holds 4,222,727 shares in Observe Medical,…

Read more

Observe Medical ASA: Final result of the subsequent offering and allocation of shares; Updated amendments of loans from Navamedic ASA to be implemented including partial conversion to shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 5 December 2024…

Read more

OBSERVE MEDICAL ASA: Preliminary results of the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 4 December 2024…

Read more

OBSERVE MEDICAL ASA: Last day of the subscription period in the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 4 December 2024…

Read more

Observe Medical ASA: Mandatory notification of trade by primary insider

Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed that Jørgen Mann, CEO and primary insider in the Company, has today purchased 100,000 shares in the Company as further specified in the attached notification form. Following the purchase, Jørgen Mann holds 600,000 shares in the Company. This information is subject to the…

Read more

Observe Medical ASA: Mandatory notification of trades by primary insider

Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed that Terje Bakken, chairman of the board and primary insider in the Company, has today purchased 100,000 shares in the Company as further specified in the attached notification form. Following the purchase Terje Bakken holds 100,000 shares in the Company. In addition, Terje…

Read more

OBSERVE MEDICAL ASA: Approval and publication of prospectus, listing of the tranche 2 private placement shares and launch of subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 19 November 2024…

Read more

Observe Medical ASA: Agreement reached with Convatec to defer payments by 12 months

Oslo, 19 November, 2024 – Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company" or "Observe Medical") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its working capital situation. The…

Read more

OBSERVE MEDICAL ASA: Resolutions to increase the share capital in connection with subsequent offering and conditional loan conversion

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 18 November 2024…

Read more

Observe Medical ASA: Amendments to loan agreements with Navamedic ASA

Oslo, 15 November 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its working capital situation. The Company has (as…

Read more

Observe Medical – DOC (Declaration of Conformity) signed for UnoMeter[TM ]Safeti[TM] Plus and subscription form for equity investment received from industrial partner

Oslo, November 12[th], 2024 – Observe Medical ("the Company" or "Observe Medical") has today signed the DOC (Declaration of Conformity). This marks the final step for the establishment of a high-volume manufacturing platform for the UnoMeter™ product portfolio, consisting of UnoMeter™ 500 and UnoMeter™ Safeti™ Plus. The DOC is the final regulatory documentation that needs to be…

Read more

OBSERVE MEDICAL ASA: First half year report 2024

Oslo, August 26, 2024 – Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2024. Business update In the first half of 2024, Observe Medical achieved growth and market expansion of the UnoMeter™ portfolio. Observe Medical has achieved a major milestone with the early commercial launch of the UnoMeter™…

Read more

Observe Medical – First order from South America

Oslo, August 22, 2024 – Observe Medical ("the Company" or "Observe Medical") has received its first order of UnoMeter 500 products from a distributor in South America. This initial order represents a significant step towards expanding our footprint in a region that holds historical importance for the UnoMeter product line. This marks a significant milestone as…

Read more

Jørgen Mann appointed permanent CEO of Observe Medical

Oslo, August 13, 2024 – Observe Medical ASA (the "Company" or "Observe Medical") announces the appointment of Jørgen Mann as its permanent Chief Executive Officer (“CEO”). Having served as interim CEO since February 2024, Mr. Mann has proven his leadership capabilities and deep insight into the Company's strategic operations. The board is fully confident in his…

Read more

Observe Medical ASA: New share capital registered

Oslo, 5 August 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per Offer Share to raise…

Read more

Allocation of offer shares to primary insiders and close associates, disclosure of share lending by person closely associated with a primary insider and mandatory notification of trade

Oslo, 17 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per Offer Share to…

Read more

Observe Medical ASA: Extraordinary general meeting held on 17 July 2024

Oslo, 17 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 26 June 2024, regarding notice of an extraordinary general meeting in connection with a private placement and contemplated subsequent offering in the Company. The extraordinary general meeting was held today,…

Read more

Observe Medical ASA: Redelivery of lent shares to persons closely associated with primary insiders and mandatory notification of trade

Oslo, 2 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 (the "Announcement"), regarding share lending by Ingerø Reiten Investment Company AS and ELI AS(jointly the "Share Lenders")in connection with the private placement of new shares in the…

Read more

Observe Medical ASA: New share capital registered

Oslo, 2 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per Offer Share to…

Read more

Observe Medical ASA: Notice of extraordinary general meeting on 17 July 2024 in connection with the private placement and a contemplated subsequent offering

Oslo, 26 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement"). In connection with completion…

Read more

Observe Medical ASA: Ex. Subsequent Offering today

OBSRV – EX. SUBSEQUENT OFFERING TODAY Issuer name: Observe Medical ASA Ex. date: 25 June 2024 Type of corporate action: Subsequent offering/repair issue Additional information: Reference is made to the stock exchange announcement published by Observe Medical ASA on 24 June 2024 with key information relating to the subsequent offering.   This information is published…

Read more

Observe Medical ASA: Disclosure of share lending by persons closely associated with primary insiders and mandatory notification of trade

Oslo, 24 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today (the "Announcement"), regarding the private placement of new shares in the Company (the "Private Placement"). As further described in the Announcement, the Private Placement consists of two tranches, of…

Read more

Observe Medical ASA: Potential equity investment from the group's largest partner within manufacturing and supply of urine measurement products

Oslo, 24 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") earlier today, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22…

Read more

Observe Medical ASA announces Letter of Intent with Sulacare for Female Catheterization Product Launch

Oslo, 4 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that it has entered into a Letter of Intent (LOI) with Sulacare AS ("Sulacare") to collaborate on the commercial launch of Sulacare's innovative and proprietary female catheterization product. This partnership goes beyond leveraging Observe Medical’s established platform to commercialize and distribute…

Read more

Observe Medical ASA – Biim Agreement with Fresenius Medical Care Extended for 2 Years

Oslo, 31 May 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that its subsidiary, Biim AS ("Biim"), has extended its agreement with Fresenius Medical Care ("Fresenius") for the supply of wireless pocketable ultrasound devices. The initial agreement with Fresenius was entered into in October 2021, with a one-year extension exercised in October…

Read more

Observe Medical announces early launch of UnoMeter[TM] Safeti Plus

Oslo, 27 May 2024 – Observe Medical ASA ("the Company" or "Observe Medical") is pleased to announce the early launch of the UnoMeter[TM] Safeti Plus, a market-leading Hourly Diuresis Monitoring System with a proven track record of safety and effectiveness. This early launch is a direct result of the strong collaboration between Observe Medical's product…

Read more

Observe Medical ASA – Minutes from Annual General Meeting

Observe Medical ASA has today, May 24, 2024, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. For further information, please contact: Jørgen Mann, Interim CEO Observe Medical Mobile:…

Read more

Observe Medical ASA – Notice of Annual General Meeting

Oslo, May 3, 2024 – Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, May 24, 2024, at 10:00 (CET). The annual general meeting will be held at Haakon VIIs gt. 1, 7th floor at Reiten & CO, 0161 Oslo, Norway. The Notice of the Annual General Meeting is attached, together…

Read more

Observe Medical Annual Report for 2023

Oslo, 30 April 2024 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2023. The Annual Report was approved by the Board of Directors on 26 April 2024. “Despite some challenges, 2023 was a year of great achievements and exciting opportunities. I am grateful…

Read more

Observe Medical transfers Nordic distribution to Vingmed

Oslo, April 18, 2024 – Observe Medical ASA (the "Company" or "Observe Medical") announces transfer of its Nordic distribution operations to Vingmed, following a strategic review. The Company assessed the relevance of the business, originally established as a platform for testing and launching its branded products. Given the expansion of our global distribution capabilities, which now…

Read more

Observe Medical – CFO resignation

Oslo, March 21, 2024 – Observe Medical ASA (the "Company" or "Observe Medical") announces that Per Arne Nygård has resigned from his position as CFO in order to pursue opportunities outside of the Company. Johan Fagerli, the current Finance Manager, will assume the responsibilities of Interim CFO effective immediately. Mr. Fagerli has been with the Company…

Read more

Observe Medical ASA: Full year and second half 2023 results

Oslo, March 13, 2024 – Observe Medical ("the Company" or "Observe Medical") today releases its results for the full year and second half of 2023. Business update The strategic acquisition of trademarks and intellectual property rights for the UnoMeter™ portfolio from Convatec, coupled with the CE certification of UnoMeter™ 500, marked 2023 as a transformative year…

Read more

Observe Medical secures framework agreement in Scotland for Unometer[TM] 500

Oslo, March 11, 2024 – Observe Medical ASA (the "Company" or "Observe Medical") announces that the Group, via its UK distributor C&P Medical, has been awarded onto the Scottish NHS Urology Framework with Unometer[TM ]500. This is a 3 year contract until end of March 2027, effective from April 2024. NHS Scotland consists of 14…

Read more

Observe Medical – Organizational changes

Oslo, February 29, 2024 -Observe Medical ASA (the "Company" or "Observe Medical") announces today that Rune Nystad has decided to step down from his role as Chief Executive Officer (“CEO”) with immediate effect to embrace new challenges within the Company. Jørgen Mann, the current Chief Commercial Officer (“CCO”), will step in as the interim CEO.…

Read more

Observe Medical – First order to Germany

Oslo, February 28, 2024 -Observe Medical ("the Company" or "Observe Medical") has received the first order for its UnoMeter products from Siramo GmbH, following the strategic Letter of Intent (LOI) announced in December 2023. This order marks the expansion into the German market, a key territory for the distribution of the UnoMeter product range. The…

Read more

Observe Medical – First orders to the Irish Hospital Market

Oslo, February 13, 2024 – Observe Medical ("the Company" or "Observe Medical") has received first orders for delivery of UnoMeter™ 500 products from our distributor in Ireland, Armstrong Medical. We are set to dispatch 2,800 units of the UnoMeter™ 500 this week, with an additional 2,500 units scheduled for shipment by the end of February. The…

Read more

Observe Medical expands into the Asian market

Oslo, January 18, 2024 – Observe Medical ("the Company" or "Observe Medical") announces the expansion of its UnoMeter portfolio into the Asian market, with UnoMeter 500 orders received from Thailand and Vietnam. This expansion not only diversifies our market presence but also reinforces Observe Medical’s commitment to global growth and establishing a strong foothold in regions…

Read more

Observe Medical – First order to Portugal

Oslo, January 4, 2024 – Observe Medical ("the Company" or "Observe Medical") has received first order from our distributor in Portugal, Aviquímica, for delivery of UnoMeter 500 products. The UnoMeter portfolio is experiencing rapid expansion, having recently secured orders from Portugal, bringing the total count to 18 countries. The favorable clinical evaluations contribute positively to the…

Read more

Observe Medical ASA – New share capital registered

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 December 2023 regarding the final results of the rights issue of 137,193,548 new shares in the Company ("Offer Shares"), each with a nominal value of NOK 0.26, at a subscription price of NOK 0.26 per share (the "Rights…

Read more

Disclosure of large shareholding

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the allocation of shares in the rights issue of 137,193,548 new shares in the Company (the "Offer Shares"), at a subscription price of NOK 0.26 per share (the "Rights Issue"). Subject to the completion of the Rights Issue, resulting…

Read more

Disclosure of large shareholding

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding the allocation of shares in the rights issue of 137,193,548 new shares in the Company (the "Offer Shares"), at a subscription price of NOK 0.26 per share (the "Rights Issue"). In connection with the Rights Issue, ELI AS has…

Read more